The Division of Psychiatry (DP) regulates and reviews Investigational New Drug (IND) applications and marketing applications for products for the treatment of psychiatric diseases and conditions, such as bipolar disorder, schizophrenia, schizoaffective disorder, major depressive disorder, attention deficit hyperactivity disorder, obsessive-compulsive disorder, panic attacks, posttraumatic stress disorder, generalized anxiety disorder, autism spectrum disorder, and insomnia.
Director: Tiffany R. Farchione, M.D. (Acting)
Deputy Director: Bernie Fischer, M.D.
Deputy Director for Safety: Marc Stone, M.D.
Safety Regulatory Project Manager: Ermias Zerislassie, Pharm.D.
Chiefs of Project Management Staff: Paul David, R.Ph. and Steve Hardeman, R.Ph.
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Psychiatry (DP)
10903 New Hampshire Avenue
Silver Spring, MD 20993
Building 22, Suite 4200
Phone: (301) 796-2260
Fax: (301) 796-9841
Resources For You
- Office of Neuroscience
- Office of New Drugs
- CDER Offices and Divisions
- Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality